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Objectives: To confirm that Kaposi’s sarcoma-associated herpes virus open-
reading frame K9, viral interferon regulatory factor 1 (vIRF1), interacts with
splicing factor, translocation liposarcoma protein-associated serine-arginine
protein (TASR), in vivo and to establish whether interactions between vIRF1 and
TASRs influence alternative splicing.
Methods: Association between vIRF1 and TASRs was confirmed with the gluta-
thione S-transferase pull-down assay and coimmunoprecipitation. Further
colocalization was shown by immunofluorescence. The in vivo splicing assay was
performed to confirm the alterations in the splicing pattern.
Results: vIRF1 interacts with both TASR1 and 2 in vivo. vIRF1 has been shown to
colocalize with TASR proteins in 293 T cells. However, an in vivo splicing revealed
no alterations in the splicing pattern via interaction.
Conclusions: The study data suggest that vIRF1 interacts with the TASR protein.
However, vIRF1 interactions do not affect TASR-mediated alternative splicing.1. Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV),
also known as human herpes virus 8, is a gamma-
herpesvirus. Epstein-Barr virus (EBV) and saimiri
herpesvirus belong to this virus group and display similar
genetic properties. KSHV triggers B cell lymphoma,
primary effusion lymphoma andmulticentric Castleman’sibuted under the terms o
y-nc/3.0) which permits un
is properly cited.
ase Control and Preventiondisease [1e3]. When the host cell is infected with a virus,
interferons (IFN) are activated as part of the immune
response, followed by triggering of various biological
activities, including suppression of tumor, apoptosis
regulated by the cell cycle, and immune activation. IFN
activation is regulated by IFN regulatory factors (IRF)
that recognize the IFN-stimulated response element
(ISRE) [4e8]. KSHV has four open reading framesf the Creative Commons Attribution Non-Commercial License
restricted non-commercial use, distribution, and reproduction in
. Published by Elsevier Korea LLC. All rights reserved.
KSHV vIRF1 interacts with TASR 9(ORF) encoding viral IRFs (vIRF) that are homologous to
the cellular IRF family [3,4,9e11].
A number of studies show that vIRF1 acts as a tran-
scriptional activator, while others have reported that
vIRF4 interacts with and inhibits transactivation of
various cellular factors [7]. For example, the tumor
suppressor p53 interacts with vIRF1, leading to repres-
sion of the transcriptional activation of p53, and
consequently, inhibition of p53-dependent apoptosis
[12,13]. vIRF1 additionally interacts with GRIM19,
a cell death regulator, and inhibits GRIM19-mediated
apoptosis in the presence of IFN/retinoic acid [14].
Moreover, malignant tumors have been generated in
nude mice injected with NIH3T3 cells stably expressing
vIRF1 [4]. These studies indicate that vIRF1 influences
KSHV tumorigenicity as a viral oncogene. vIRF1 also
interacts with the transcriptional coactivator, p300/
CREB, and inhibits transcription of the IFNA gene by
suppressing the transactivation of cellular IRFs. Earlier
studies have additionally reported that vIRF1 suppresses
cellular cytokine expression by inhibiting the histone
acetyltransferase activity of p300 [9,15,16]. Thus, vIRF1
clearly alters the expression patterns of cellular factors.
The serine-arginine (SR) protein family is important
for pre-mRNA splicing. These proteins contain two
major domains. The N-terminus of SR proteins consists
of ribonucleoprotein-type RNA binding domains that
interact with pre-mRNA, and the C-terminus includes an
arginine-serine (RS) domain required for protein-protein
interactions [17,18].
The SR splicing factors, translocation liposarcoma
protein (TLS)-associated serine-arginine proteins
(TASRs), have been classified into two isoforms, TASR
1 and 2, composed of 183 and 262 aa, respectively. The
proteins share a common N-terminal domain, but differ
in the C-terminal domain. An earlier in vivo E1A
splicing assay revealed differential splicing patterns.
TASR 1 induces splicing to the 11S and 10S isoforms,
and TASR2 to the 9S isoform [19e21]. Additionally,
TASR 1 contributes to alternative splicing of type II and
XI collagen genes in chondrogenic cells, but TASR2
does not [22]. TASRs interact with TLS or Ewing’s
sarcoma (EWS) proteins through the C-terminus. Nor-
mally, TLS and EWS link the gene transcription of RNA
polymerase II to RNA splicing of TASRs. Upon
replacement of the C-terminus with ETS-related gene
and Friend leukemia integration-1, alternative splicing
through TASRs was disrupted, and human myeloid
leukemia and sarcoma were triggered, respectively
[20,21,23e25].
Previously, we identified an association between
TASRs and vIRF1 using the yeast two-hybrid assay
[14]. Interactions with vIRF1 potentially influence the
functions of cellular proteins, and we therefore assumed
that vIRF1 affects the splicing function of TASRs via
binding. However, the results indicate that vIRF1 does
not affect the splicing function of TASRs.2. Materials and Methods
2.1. Plasmids
To construct Flag-tagged TASR1 and TASR2, TASR
cDNA was amplified from pcDNA3-TASR1 and
pcDNA3-TASR2, respectively. The forward TASR
primer, 50 CCC GAA TTC ATG TCC CGC TAC CTG
CGT 30, reverse TASR1 primer, 50 GGG CTC GAG TCA
GTGGCCACTGGACTT30, and reverse TASR2primer,
50 GGG CTC GAG TCA GAT CTT TCT TGA AGT
GTA 30, were employed for amplification. Sequences
were subcloned into the EcoRI/XhoI site of the Flag-
tagged vector, pME18S.
2.2. Cell culture and transfection
293 T and COS-1 cells were grown in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine
serum and 1% antibiotics. For the binding assay, 293 T
cells were cotransfected with pEBG or pEBG-vIRF1
and pME18S-TASR1 or pME18S-TASR2 using the
calcium phosphate method. For the immunofluorescence
assay, 293 T cells were cotransfected with pEGFP-C1-
vIRF1 and pME18S-TASR using PolyExpress reagents
(Excellgen, Rockville, MD). COS-1 cells were trans-
fected with pCS3-MT-E1A, pME18S-TASRs, and
pcDNA3-vIRF1, using the same reagents.
2.3. Glutathione S-transferase pull-down assay
and western blotting
At 48 h posttransfection, 293 T cells were lysed in
EBC buffer (50 mM Tris-HCl [pH7.5], 120 mM NaCl,
50 mM NaF, 0.5% Nonidet P-40, 1 mM phenyl-
methylsulfonyl fluoride). Cell lysates were incubated with
glutathione sepharose 4B beads (Amersham Pharmacia
Biotech, Cardiff, UK) for 2 h at 4 C. Glutathione S-
transferase (GST) fusion protein and GST bead
complexes were washed with EBC buffer. Samples were
mixed with loading buffer, heated at 100 C, separated
with SDS-PAGE on a 10% gel, and transferred to PVDF
membrane. Proteins were immunoblotted with a mono-
clonal mouse anti-Flag antibody (Sigma-Aldrich, Poole,
United Kingdom), and bands detected with the enhanced
chemiluminescence analysis system (Thermo Scientific,
Woburn, MA, USA).
2.4. Coimmunoprecipitation
Transfected 293 T cells were lysed in EBC buffer
at 48 h posttransfection. Lysates were centrifuged at
2440g for 20 min. Supernatant fractions were initially
incubated with monoclonal mouse anti-Flag antibody for
1 h at 4 C with rocking, and subsequently with protein G
Sepharose 4 Fast Flow (GE Healthcare, Waukesha, WI,
USA) beads for 1 h at 4 C. Flag fusion protein and bead
complexes were washed with EBC buffer 4 times.
Samples were mixed with loading buffer and heated at
100 C for SDS-PAGE. Proteins were separated using
10 S. Kim, et alSDS-PAGE, and immunoblotted with an anti-GST
antibody.
2.5. Immunofluorescence
Transfected 293 T cells were fixed with 3.7% formal-
dehyde for 15 min, and permeabilized with phosphate-
buffered saline (PBS) containing 0.2% Triton X-100
(PBST) for 10 min. Cells were blocked with PBST con-
taining 1% bovine serum albumin for 30 min, incubated
with anti-Flag antibodies for 1 h, and washed 3 times with
PBST. Next, cells were incubated with rhodamine-
conjugated anti-mouse IgG antibodies for 1 h, washed 3
times with PBST, and analyzed using confocal micros-
copy (FV-1000; Olympus, Tokyo, Japan).
2.6. E1A pre-mRNA splicing assay
COS-1 cells were cotransfected with 0.25 mg of
pCS3-MT-E1A, 1.5 mg of pcDNA3-vIRF1 and 0.25 mg
of pME18S-TASR1 or 2 using PolyExpress reagents.
The total amount of DNA was adjusted with corre-
sponding empty vectors. After 24 h, total RNA was
extracted with TRIzol reagent and reverse-transcribedFigure 1. Interactions of vIRF1 with TASR1 or 2 in vivo. (A) 293
TASR1 expression plasmids. Cells were lysed with EBC buffer, an
GST fusion and Flag fusion proteins were detected using western
(bottom panel), respectively. Lanes 1, 3, GST and Flag-TASR1
cotransfected with GST or GST-vIRF1 and Flag-TASR2 express
specified in Panel A. Lanes 5, 7, GST and Flag-TASR2; Lanes 6, 8
A. 293 T cells were cotransfected with GST or GST-vIRF1 and F
with anti-Flag antibody and precipitated with protein G-Sepharose b
by western blotting with anti-GST and anti-Flag antibodies respectiv
and Flag-TASR1 (D) Reciprocal assay for Panel B. 293 T cells were
Flag-TASR2, and subjected to similar experiments as those specifi
GST-vIRF1 and Flag-TASR1.with oligo(dT) primers. Various E1a splice forms were
amplified with these primers. The forward primer used
was 5’-GAG CTT GGG CGA CCT CA-3’ (RR67) and
reverse primer was 5’-TCT AGA CAC AGG TGA TGT
CG-3’ (E1A2). PCR products were separated on a 1.5%
agarose gel containing ethidium bromide and analyzed
with gel documentation.3. Results
3.1. vIRF1 interacts with TASR1 and TASR2
in vivo
Having previously confirmed the association of vIRF1
and TASR1 using the yeast two-hybrid assay [14], we
aimed to further ascertain whether TASR2 also interacts
with vIRF1, since both isoforms contain identical N-
terminal domains. To identify the in vivo interactions, 293
T cells were cotransfected with GST or GST-vIRF1, and
Flag-TASR1 or Flag-TASR2 expression plasmids. At 48 h
posttransfection, proteins were extracted from transfected
cells, and GST and GST-vIRF1 precipitated withT cells were cotransfected with GST or GST-vIRF1 and Flag-
d cell extracts incubated with glutathione sepharose 4B beads.
blotting with anti-GST (top panel) and anti-Flag antibodies
; 3, 4, GST-vIRF1 and Flag-TASR1 (B) 293 T cells were
ion plasmids and subjected to similar experiments as those
, GST-vIRF1 and Flag-TASR2. (C) Reciprocal assay for Panel
lag-TASR1 expression plasmids. Cell extracts were incubated
eads for 1 h. GST fusion and Flag fusion proteins were detected
ely. Lanes 1, 3, GST and Flag-TASR1; Lanes 2, 4, GST-vIRF1
cotransfected with GST or GST-vIRF1 expression plasmid and
ed in panel C. Lanes 5, 7, GST and Flag-TASR1; Lanes 6, 8,
KSHV vIRF1 interacts with TASR 11glutathione sepharose 4B beads. Proteins were separated
via SDS-PAGEand thewestern blot assay performed using
an anti-Flag antibody. Both Flag-TASR1 and Flag-TASR2
coprecipitated with GST-vIRF1 (Figure 1A, Lane 4, and
Figure 1B, Lane 8), but not GST alone (Figure 1A, Lane 3,
Figure 1B, Lane 7). To verify the correct expression of
GST, GST-vIRF1, Flag-TASR1, and Flag-TASR2
proteins, whole-cell lysates were immunoblotted using
anti-GST and anti-Flag antibodies (Figure 1A Lane 1, 2
and Figure 1B Lane 5, 6). In a reciprocal assay, cell lysates
were incubated with anti-Flag antibody for 1 h, followed
by proteinG-Sepharose beads for 1 h. Precipitated proteins
were separated by SDS-PAGE and immunoblotted using
ananti-GSTantibody.GST-vIRF1was coprecipitatedwith
Flag-TASR1 and Flag-TASR2 (Figure 1C, Lane 4, and
Figure 1D, Lane 8). To establish whether proteins were
expressed correctly,western blot assay for total lysateswas
performed (Figure 1C, Lanes 1, 2, and Figure 2C, Lanes 5,
6). Our results indicate that vIRF1 interacts with both
TASR1 and TASR2 in mammalian cells.3.2. vIRF1 colocalizes with TASR1 and TASR2
To confirm colocalization of vIRF1 with TASRs, we
performed immunofluorescence assay. Green fluores-
cent protein (GFP)-vIRF1 proteins were predominantly
expressed in the nucleus, while GFP was expressed inFigure 2. Colocalization of vIRF1 and TASR1 or 2. (A) GFP, G
293 T cells, respectively. Cells were fixed at posttransfection 24 h.
antibody and detected with TRITC-conjugated anti-mouse-antibod
Flag-TASR1 were localized in the nucleus. (C) Colocalization of vnucleus and cytoplasm. Flag-TASR1 and 2 were mostly
localized in the nucleoplasm. 293 T cells were further
cotransfected with GFP-vIRF1 and Flag-TASR1 or 2
expression plasmids, and the expression patterns
analyzed using confocal microscopy. Notably, vIRF1
colocalized with TASR1 and 2 in the nucleus, particu-
larly within the nucleoplasm region (Figure 2).
3.3. vIRF1 has no effect on E1A mRNA splicing
mediated by TASR1 and 2
TASR1 and 2 are known splicing factors. In view of
the finding that TASR1 and 2 interact with vIRF1, we
subsequently examined whether vIRF1 affects the splicing
function of TASRs. The well-characterized E1A reporter
gene is commonly employed for analysis of splicing. E1A
pre-mRNA exists as five spliced isoforms (Figure 3A).
Cos-1 cells were transfected with various combinations of
E1A reporter plasmids, TASRs, and vIRF1 (Figure 3B,
top). TotalRNAwas extracted, andRT-PCRperformed for
amplification of the E1A pre-mRNA isoforms. COS-1
cells mainly transfected with E1A reporter plasmids
generated 13S, 12S, and 9S isoforms (Figure 3B Lane 1).
Overexpression of TASR1 induced the generation of 11S,
10S and 9S, while TASR2 promoted an increase in the 9S
isoform (Figure 3B, Lanes 3 and 5). Coexpression of
vIRF1 did not affect TASR-mediated E1A mRNA
splicing (Figure 3B, Lanes 4 and 6).FP-vIRF1, Flag-TASR1 and Flag-TASR2 were transfected in
Flag-TASR1/2-expressing cells were incubated with anti-Flag-
y. (B) Colocalization of vIRF1 and TASR1. Both vIRF1 and
IRF1 and TASR2 (x 600 magnification).
Figure 3. In vivo E1A splicing assay. (A) Diagram of E1A
pre-mRNA splicing isoforms. RT-PCR primers are represented
by arrows (RR67: forward primer, E1a2: reverse primer). (B)
In vivo E1A splicing assay. COS-1 cells were cotransfected
with pCS3-MT-E1A, pcDNA3-vIRF1 and pME18S-TASR1 or
2. After 24 h, total RNA was extracted and reverse-transcribed
using oligo(dT) primers. E1A pre-mRNA splicing isoforms
were amplified with a pair of specific primers, as described in
Panel A.
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KSHV proteins are significantly homologous to host
cellular proteins, and may be essential to avoid host
immune surveillance activated by viral infections [6]. In
particular, vIRF1 (ORF9), which is homologous to
cellular IRF, inhibits transcriptional processes regulated
by types I and II IFN and the tumor suppressor, IRF1
[4,26]. Moreover, vIRF1 interacts with p53 and GRIM19,
leading to the prevention of p53-dependent and GRIM19-
induced apoptosis, respectively. Based on these results,
we assumed that vIRF1 affects the tumorigenicity of
KSHV as a repressor of cell cycle regulation [12e14].
We identified that TASR1 interacts with vIRF1 using
the yeast two-hybrid assay (data not shown). Both
TASR1 and TASR2 displaying sequence homology to
TASR1 interacted with vIRF1 in vivo (19). TASR1 and 2
colocalized with vIRF1 in the nucleus. TASRs, initially
identified from a yeast two-hybrid assay for TLS, are
recruited to TLS or EWS. In human myeloid leukemia
and malignant liposarcoma, the TLS C-terminus is
replaced with ERG or CHOP fusion protein, respec-
tively. Thus, SR proteins cannot be recruited to TLS, and
SR-mediated E1A pre-mRNA splicing is effectively
prevented [20,21]. We assume that if vIRF1 inhibits thesplicing function of TASRs, interactions between these
proteins should affect tumorigenicity, since both vIRF1
and TASR1 can induce tumors. Accordingly, we aimed
to establish whether interactions between vIRF1 and
TASRs influence alternative splicing. An in vivo splicing
assay was performed to clarify this issue. In contrast to
our expectation, vIRF1 did not appear to alter the TASR-
mediated splicing site selection via inhibition of TASR
function. In case of effects on splicing, vIRF1 should be
able to regulate the host system at the posttranscriptional
level. However, vIRF1-TASR interactions did not
influence RNA processing.Acknowledgement
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